Guidi L, Pugliese D, Tonucci TP, et al. - In this prospective observational study, researchers assessed the usefulness of an early vedolizumab trough level assay for anticipating the first-year vedolizumab therapy result. This investigation was carried out at two Italian referral inflammatory bowel disease (IBD) centres. Between August 2016 to December 2017, patients with consecutive IBD were included. At weeks 6 and 14, vedolizumab trough levels and anti-vedolizumab antibodies were measured. At weeks 6, 14, 22 and 54, clinical outcome was evaluated. The study sample consisted of 101 patients initiating vedolizumab. Due to sustained clinical benefit, high vedolizumab trough level at week 14 was linked to a higher probability of maintaining vedolizumab therapy during the first year. In addition, within the first year, vedolizumab trough level appeared to predict clinical and endoscopic remissions at weeks 6 and 14.